2013年から2025年にかけてのFDA有害事象報告システム (FAERS) データベースを利用したカルバペネム関連薬剤の医薬品警戒分析
1Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada.
The Journal of antimicrobial chemotherapy
|February 20, 2026
まとめ
メロペネムは,骨髄不全とアグラヌロサイトーシスを含む,カルバペネムの中で最も広範な重度の血液学的毒性のスペクトルを示しています. ドリペネムは,この医薬品警戒研究で報告された血液学的安全性信号を示さなかった.
科学分野:
- 薬理学 薬理学とは
- 血液学 ヘマトロジ
- 感染症 感染症は感染症です.
背景:
- カーバペネム抗生物質は,多剤耐性感染症の治療に不可欠です.
- カーバペネムの比較血液学的安全性プロファイルは十分に確立されていません.
- この研究は,カルバペネムに関連した血液学的有害事象を特徴づける必要性に対処しています.
研究 の 目的:
- 4種類のカルバペネム抗生物質であるメロペネム,エルタペネム,イミペネム,ドリペネムの血液学的安全性プロフィールを体系的に評価し,比較する.
- 各カルバペネムに関連した特定の血液学的有害事象を特定するために.
- 異なる安全性プロファイルに基づいてカルバペネムの臨床選択を図る.
主な方法:
- 2013年1月から2025年7月までのFDA有害事象報告システム (FAERS) データベースの分析.
- 確率比率 (ROR) と95%信頼区間を報告する不均衡分析を使用しました.
- 16の異なる血液学的有害事象に焦点を当てた.
主要な成果:
- メロペネムは,血栓細胞症,エオシノフィリア,骨髄不全,アグラヌロサイト症,およびパンチトペニアを含む15の血液学的有害事象に対する有意な信号を示した.
- イミペネムとエルタペネムはそれぞれ9つのイベントのシグナルを示し,注目に値するイベントには,血小板減少症,エオシノフィリア,白血症,中性子減少症が含まれています.
- ドリペネムに対する血液学的有害事象の報告は確認されなかった.
結論:
- 血液学的安全性プロファイルには,カルバペネム類の間で顕著な差異がある.
- メロペネムは,重度の血液学的毒性の最も広範なスペクトルを示しています.
- 異なる安全性プロファイルは,カルバペネムの選択に考慮することを正当化します,特に既にある血液学的状態の患者にとって.
さらに関連する動画
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
27.8K
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
13.5K
関連する概念動画
01:19Pharmacovigilance
1.8K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.8K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
01:26Pharmaceutical Poisoning: Potential Scenarios
22
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
22
01:29Therapeutic Drug Monitoring: Affecting Factors
266
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
266
01:26FDA Approved Drugs: Changes to Approved Drugs
289
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
289
01:12Analysis of Population Pharmacokinetic Data
830
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
830